BRIEF published on 11/13/2025 at 07:35, 1 month 4 days ago Dermapharm maintient sa stabilité malgré les ajustements de son portefeuille Croissance Et Bénéfices Dermapharm Restructuration Du Portefeuille Résultats Financiers De 2025 Médicaments De Marque
BRIEF published on 11/13/2025 at 07:35, 1 month 4 days ago Dermapharm Maintains Stability Amid Portfolio Adjustments Growth And Earnings Branded Pharmaceuticals Dermapharm 2025 Financial Results Portfolio Restructuring
PRESS RELEASE published on 11/13/2025 at 07:30, 1 month 4 days ago Stable earnings despite portfolio adjustment - 2025 guidance confirmed, strong growth in branded pharmaceuticals Dermapharm Holding SE reports stable earnings despite portfolio adjustments in Q3 2025, confirms 2025 guidance and strong growth in branded pharmaceuticals Pharmaceuticals Growth Earnings Dermapharm Holding SE Portfolio Adjustment
BRIEF published on 08/26/2025 at 07:35, 3 months 22 days ago Dermapharm annonce une activité stable au premier semestre 2025 et une croissance de l'EBITDA au deuxième trimestre Résultats Financiers Croissance De L'EBITDA Stabilité Des Revenus Produits Pharmaceutiques De Marque Performances De Dermapharm
BRIEF published on 08/26/2025 at 07:35, 3 months 22 days ago Dermapharm Reports Stable Business in H1 2025 and Q2 EBITDA Growth Financial Results EBITDA Growth Revenue Stability Branded Pharmaceuticals Dermapharm Performance
PRESS RELEASE published on 08/26/2025 at 07:30, 3 months 22 days ago Dermapharm confirms stable business development in H1 2025 and records EBITDA growth in Q2 versus prior-year quarter Dermapharm confirms stable business development in H1 2025 with EBITDA growth in Q2. Full-year guidance for 2025 reiterated. Branded pharmaceuticals main growth driver Revenue Pharmaceuticals EBITDA Growth Dermapharm H1 2025
BRIEF published on 08/12/2025 at 07:35, 4 months 5 days ago Dermapharm Holding SE poursuit sa croissance au deuxième trimestre 2025 Prévisions De Revenus Croissance De L'EBITDA Produits Pharmaceutiques De Marque Dermapharm Performances Du Deuxième Trimestre 2025
BRIEF published on 08/12/2025 at 07:35, 4 months 5 days ago Dermapharm Holding SE Continues Growth in Q2 2025 Revenue Forecast EBITDA Growth Branded Pharmaceuticals Dermapharm Q2 2025 Performance
PRESS RELEASE published on 08/12/2025 at 07:30, 4 months 5 days ago Dermapharm Holding SE remains on projected growth trajectory in Q2 2025 Dermapharm Holding SE reports Q2 2025 results in line with expectations. Confirms full-year guidance of EUR 1,160–1,200 million revenue and EUR 322–332 million EBITDA Pharmaceuticals EBITDA Growth Dermapharm Holding SE Full-year Guidance Q2 2025 Results
BRIEF published on 06/26/2025 at 17:48, 5 months 21 days ago Dermapharm Holding SE Approves EUR 0.90 Dividend Per Share Sustainability Dividend AGM Financial Outlook Dermapharm
Published on 12/17/2025 at 23:15, 26 minutes ago Northern Superior Announces the Ratio for the Distribution of the Common Shares in the Capital of ONGold Resources Ltd.
Published on 12/17/2025 at 15:00, 8 hours 41 minutes ago BlackBerry Unveils Ground-Up Modernization of BlackBerry AtHoc Mobile Experience to Enable More Intelligent Operations
Published on 12/17/2025 at 14:00, 9 hours 41 minutes ago UniDoc Completes H3 Health Cube Installation in Italy
Published on 12/17/2025 at 13:35, 10 hours 6 minutes ago Silver X Mining Announces Grant of Incentive Stock Options and Restricted Share Units
Published on 12/17/2025 at 13:15, 10 hours 26 minutes ago Aclara Wins UN Global Compact Award for Its Contribution to Local Employment and Suppliers
Published on 12/17/2025 at 22:05, 1 hour 36 minutes ago Abivax annonce l’acceptation de 22 abstracts sur obefazimod dans les MICI à l’ECCO 2026, dont une présentation orale sur des résultats précliniques antifibrotiques
Published on 12/17/2025 at 22:05, 1 hour 36 minutes ago Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
Published on 12/17/2025 at 21:22, 2 hours 19 minutes ago EQS-Adhoc: DATAGROUP SE: DATAGROUP SE Management Board plans dividend of EUR 0.04 per share
Published on 12/17/2025 at 20:12, 3 hours 29 minutes ago EQS-Adhoc: Rheinmetall AG: Executive Board decides to sell activities of the civil division Power Systems – Target is sale in the first quarter of 2026; update of outlook for continuing operation
Published on 12/17/2025 at 19:39, 4 hours 1 minute ago Avolta awarded Shanghai Pudong International Airport concession, marking a first-in-a-generation duty-free win for an international operator in mainland China
Published on 12/17/2025 at 20:39, 3 hours 2 minutes ago Aeroports de Paris SA | 2026 Airport charges in Paris
Published on 12/17/2025 at 20:39, 3 hours 2 minutes ago Aeroports de Paris SA | Tarifs des redevances aeroportuaires 2026 à Paris
Published on 12/17/2025 at 19:30, 4 hours 11 minutes ago Evolution de la composition du Conseil d’Administration
Published on 12/17/2025 at 18:00, 5 hours 41 minutes ago Outstanding Shares and Voting Rights Statement at 30 November 2025
